OECD report calls for further reforms in China to boost R&D

9 September 2007

China's impressive growth in R&D spending will not achieve satisfactory returns on investment unless a redirection is made from the current emphasis on experimental research for new products and in high-technology sectors, towards basic research, which has longer-term benefits, according to a report by the Paris, France-headquartered Organization for Economic Cooperation and Development. The international agency has called on the Chinese government to provide for more R&D in services, energy, environmental technology and basic research.

The OECD also notes that, despite China having more researchers than any country apart from the USA, the recent drop in the number of undergraduate science students could lead to a shortage of skilled science and technology staff.

Reforms to the largely state-owned banking system and to lax intellectual property rights, the latter particularly affecting drugmakers (Marketletters passim), would also benefit China's business innovation, the international body argued.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight